Cildag Songul
Immunology-Allergy Department, Adnan Menderes University, Turkey.
Med Pharm Rep. 2019 Jan;92(1):91-93. doi: 10.15386/cjmed-1082. Epub 2019 Jan 15.
Omalizumab is recommended as a third-line treatment in the treatment of chronic spontaneous urticaria. During omalizumab use, which has high efficacy and safety, the side effects observed are usually moderate and temporary. Here we discuss the triggering of atrial fibrillation following omalizumab injection.
A 72-year-old female patient was treated with omalizumab 300 mg/day due to chronic spontaneous urticaria resistant to conventional treatments. Atrial fibrillation developed 6 hours after the second injection of omalizumab in the patient who had atrial fibrillation and who had been monitored with antiarrhythmic treatment and sinus rhythm for 1 year. The treatment was discontinued because omalizumab was thought to trigger atrial fibrillation, as no other reason to explain the triggering of atrial fibrillation could be found.
There is no data in the literature on the use of omalizumab in patients with atrial fibrillation. Different side effects of biological treatments can be observed. In particular, omalizumab should be used with caution in elderly patients and patients with arrhythmia.
奥马珠单抗被推荐作为慢性自发性荨麻疹治疗的三线用药。在使用奥马珠单抗期间，其疗效高且安全性好，观察到的副作用通常为中度且是暂时的。在此，我们讨论奥马珠单抗注射后引发心房颤动的情况。
一名72岁女性患者因对传统治疗耐药的慢性自发性荨麻疹接受300毫克/天的奥马珠单抗治疗。该患者曾患心房颤动且接受抗心律失常治疗并维持窦性心律1年，在第二次注射奥马珠单抗6小时后发生心房颤动。由于未发现其他可解释心房颤动发作的原因，且认为奥马珠单抗引发了心房颤动，故停用该治疗。
文献中尚无关于心房颤动患者使用奥马珠单抗的相关数据。生物治疗可观察到不同的副作用。特别是，奥马珠单抗在老年患者和心律失常患者中应谨慎使用。
